Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma.
chemoresistance
claudin-6
prognostic factor
proteomics
uterine cervical adenocarcinoma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
09
01
2022
received:
06
10
2021
accepted:
24
01
2022
pubmed:
1
2
2022
medline:
12
4
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
Recent studies have revealed that aberrant expression of tight junction (TJ) proteins is a hallmark of various solid tumors and it is recognized as a useful therapeutic target. Claudin-6 (CLDN6), a member of the family of TJ transmembrane proteins, is an ideal therapeutic target because it is not expressed in human adult normal tissues. In this study, we found that CLDN6 is highly expressed in uterine cervical adenocarcinoma (ADC) and that high CLDN6 expression was correlated with lymph node metastasis and lymphovascular infiltration and was an independent prognostic factor. Shotgun proteome analysis revealed that cell-cell adhesion-related proteins and drug metabolism-associated proteins (aldo-keto reductase [AKR] family proteins) were significantly increased in CLDN6-overexpressing cells. Furthermore, overexpression of CLDN6 enhanced cell-cell adhesion properties and attenuated sensitivity to anticancer drugs including doxorubicin, daunorubicin, and cisplatin. Taken together, the results indicate that aberrant expression of CLDN6 enhances malignant potentials and drug resistance of cervical ADC, possibly due to increased cell-cell adhesion properties and drug metabolism. Our findings provide an insight into a new therapeutic strategy, a CLDN6-targeting therapy, against cervical ADC.
Identifiants
pubmed: 35100472
doi: 10.1111/cas.15284
pmc: PMC8990859
doi:
Substances chimiques
Claudins
0
claudin 6
MRC5FX426I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1530Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K07409
Organisme : Japan Society for the Promotion of Science
ID : JP20K16196
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93
pubmed: 11283726
Cancer Sci. 2022 Apr;113(4):1519-1530
pubmed: 35100472
Science. 2020 Jan 24;367(6476):446-453
pubmed: 31896660
Histopathology. 2012 Dec;61(6):1043-56
pubmed: 22803571
Exp Cell Res. 2003 Jun 10;286(2):288-97
pubmed: 12749857
Exp Cell Res. 2001 Feb 1;263(1):163-72
pubmed: 11161715
Histol Histopathol. 2020 Apr;35(4):351-359
pubmed: 31483053
Oncol Lett. 2014 Mar;7(3):674-678
pubmed: 24527071
Pathol Int. 2013 Jan;63(1):1-12
pubmed: 23356220
Gynecol Oncol. 2000 Aug;78(2):97-105
pubmed: 10926787
Biochim Biophys Acta Mol Cell Res. 2020 Apr;1867(4):118642
pubmed: 31923533
Oncoimmunology. 2015 Oct 29;5(3):e1091555
pubmed: 27141353
Int J Cancer. 1998 Feb 9;75(4):536-45
pubmed: 9466653
Cancer Cell. 2019 Mar 18;35(3):347-367
pubmed: 30889378
Sci Rep. 2016 Sep 19;6:33582
pubmed: 27641742
Lancet. 2001 May 12;357(9267):1490-3
pubmed: 11377601
Am J Pathol. 2019 May;189(5):1015-1028
pubmed: 30790560
Drug Metab Rev. 2008;40(4):553-624
pubmed: 18949601
Gastric Cancer. 2021 May;24(3):721-730
pubmed: 33755863
Pflugers Arch. 2017 Jan;469(1):55-67
pubmed: 27624415
Cancers (Basel). 2020 Sep 24;12(10):
pubmed: 32987797
Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57
pubmed: 19546857
Dev Dyn. 2001 Oct;222(2):292-300
pubmed: 11668606
Gynecol Oncol. 2010 Jan;116(1):140-6
pubmed: 19880165
Dev Dyn. 2004 Oct;231(2):425-31
pubmed: 15366020
Int J Cancer. 2005 Mar 1;113(6):1005-9
pubmed: 15515017
Dev Dyn. 2008 Feb;237(2):504-12
pubmed: 18213590
Toxicol Appl Pharmacol. 2014 Aug 1;278(3):238-48
pubmed: 24832494
Cancer Res. 2019 Mar 15;79(6):1252-1259
pubmed: 30635276
Curr Opin Cell Biol. 2001 Oct;13(5):541-5
pubmed: 11544021
Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24600-24609
pubmed: 31740618
J Gynecol Oncol. 2017 Mar;28(2):e19
pubmed: 28028992
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9
pubmed: 16172231
Gynecol Oncol. 2000 Nov;79(2):289-93
pubmed: 11063659
J Cell Mol Med. 2020 Jun;24(11):6438-6447
pubmed: 32307891
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Oncol. 2011 Oct;22(10):2166-78
pubmed: 21325449
Histopathology. 2013 Jan;62(1):138-60
pubmed: 23134447
Oncogene. 2008 Nov 24;27(55):6930-8
pubmed: 19029935
Int J Mol Sci. 2020 Aug 17;21(16):
pubmed: 32824620
PLoS One. 2015 Dec 14;10(12):e0144887
pubmed: 26660311
Cell Tissue Res. 2013 Jan;351(1):73-84
pubmed: 23073616
Am J Respir Cell Mol Biol. 2017 Apr;56(4):443-452
pubmed: 27922761
Cancer Lett. 2017 Sep 10;403:66-73
pubmed: 28624624
Cancer Sci. 2017 Nov;108(11):2306-2314
pubmed: 28837251
Neoplasia. 2018 Oct;20(10):1083-1093
pubmed: 30227306
Chem Biol Drug Des. 2011 Feb;77(2):124-36
pubmed: 21266016
Gynecol Oncol. 1996 Feb;60(2):245-50
pubmed: 8631546
Histol Histopathol. 2016 Aug;31(8):921-31
pubmed: 26847087
Gynecol Oncol. 2012 Oct;127(1):114-20
pubmed: 22728518
PLoS One. 2013 Oct 08;8(10):e75106
pubmed: 24116027
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30487436
Cancer Sci. 2021 Feb;112(2):906-917
pubmed: 33185939
Cancer Sci. 2020 Aug;111(8):3071-3081
pubmed: 32530543
J Oncol. 2010;2010:541957
pubmed: 20671913
Biochem Biophys Res Commun. 2021 Aug 6;565:36-42
pubmed: 34090208
Front Med (Lausanne). 2021 Jul 28;8:682366
pubmed: 34395473
Am J Surg Pathol. 2012 Jan;36(1):73-80
pubmed: 21989342
J Exp Clin Cancer Res. 2017 Nov 7;36(1):157
pubmed: 29116019
J Biol Chem. 2020 Feb 21;295(8):2495-2505
pubmed: 31937589
Med Mol Morphol. 2019 Mar;52(1):23-35
pubmed: 29955965
Gastric Cancer. 2020 May;23(3):403-417
pubmed: 31654186